Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis
solutions company, is furthering its mission to advance the next
generation of high parameter cell analysis by continuing to have an
active presence at key industry events worldwide. The company’s
Full Spectrum Profiling™ (FSP™) technology that streamlines
workflows, accelerates discoveries and maximizes efficiency will be
front and center at both the European Society for Clinical Cell
Analysis’ (ESCCA) 2023 Conference in September and the 38th
International Clinical Cytometry (ICCS) Meeting & Course in
October.
Cytek will be on hand at ESCCA 2023 in Utrecht,
the Netherlands from September 27-30 to showcase its complete cell
analysis solutions that enable scientists to advance their
research, gain deeper insights, and fast-track discovery. Attended
by hematologists, immunologists, microbiologists, laboratory
medicine specialists, researchers, technicians, laboratory managers
and staff, and pharma biologists related to clinically applied flow
cytometry, ESCCA provides a forum for education and scientific
exchange.
At the conference, Dr. Manuel Ramirez, Head of
Oncology Research Lab for Madrid’s Hospital Infantil Universitario
Niño Jesús, will lead a symposium focused on the process of
designing and optimizing a 24-color B cell panel for use with
childhood B-ALL, including considerations for choice of
fluorochromes. Dr. Ramirez will share data that points to the fact
that the unique full spectrum approach employed by the Cytek®
Northern Lights™-CLC flow cytometer, complemented by a novel
optical design and robust unmixing algorithm, increases laboratory
efficiency by allowing more information to be gleaned from a single
tube – saving time and resources. The symposium will take place on
Thursday, September 28, 2023, from 3:00-3:30 p.m. CET.
“Cancer treatment is an ever-evolving field,
with clinical researchers and clinicians constantly striving to
improve diagnostics and treatment,” said Dr. Ramirez. “While flow
cytometers have become a standard tool in our arsenal, Cytek is
truly shaping the future of what is possible through cell analysis
with its revolutionary spectral technologies.”
The ICCS Annual Meeting & Course in New
Orleans seeks to help participants increase their knowledge of
current tools and technologies available for patient sample
analysis, better understand the accepted methodologies and
benchmarks for patient sample analysis and diagnosis, and increase
their competence in using analytical software applications. To that
end, Cytek will conduct a ‘Lunch and Learn’ presentation that
focuses on the critical roles panel design and assay optimization
play in laboratory developed tests (LTDs). Hosted by Paul K.
Wallace, Ph.D., Professor Emeritus at the Roswell Park
Comprehensive Cancer Center in Buffalo, New York, this presentation
will take place on Sunday, October 1, 2023, at 12:00 p.m. CT.
For more information, please visit
www.cytekbio.com.
About Cytek Biosciences,
Inc.
Cytek Biosciences (Nasdaq: CTKB) is a leading
cell analysis solutions company advancing the next generation of
cell analysis tools by delivering high-resolution, high-content and
high-sensitivity cell analysis utilizing its patented Full Spectrum
Profiling™ (FSP™) technology. Cytek’s novel approach harnesses the
power of information within the entire spectrum of a fluorescent
signal to achieve a higher level of multiplexing with precision and
sensitivity. Cytek’s FSP platform includes its core instruments,
the Aurora and Northern Lights™ systems; its cell sorter, the
Aurora CS; the flow cytometer and imaging products under the Amnis®
and Guava® brands; and reagents, software and services to provide a
comprehensive and integrated suite of solutions for its customers.
Cytek is headquartered in Fremont, California with offices and
distribution channels across the globe. More information about the
company and its products is available at www.cytekbio.com.
Cytek’s products are for research use only and
not for use in diagnostic procedures (other than Cytek’s Northern
Lights-CLC system and certain reagents, which are available for
clinical use in China and the European Union).
Cytek, Full Spectrum Profiling, FSP, Northern
Lights, Amnis and Guava are trademarks of Cytek Biosciences,
Inc.
In addition to filings with the Securities and
Exchange Commission (SEC), press releases, public conference calls
and webcasts, Cytek uses its website (www.cytekbio.com), LinkedIn
page and X (formerly Twitter) account as channels of
distribution of information about its company, products, planned
financial and other announcements, attendance at upcoming investor
and industry conferences and other matters. Such information may be
deemed material information and Cytek may use these channels to
comply with its disclosure obligations under Regulation FD.
Therefore, investors should monitor Cytek’s website, LinkedIn page,
and X account in addition to following its SEC filings, news
releases, public conference calls and webcasts.
Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 as
contained in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are subject to the “safe harbor” created by those sections.
All statements, other than statements of historical facts, may be
forward-looking statements. Forward-looking statements generally
can be identified by the use of forward-looking terminology such as
“may,” “might," "will,” “should,” “expect,” “plan,” “anticipate,”
“could,” “intend,” “target,” “project,” “contemplate,” “believe,”
“estimate,” “predict,” “potential” or “continue” or the negatives
of these terms or variations of them or similar terminology, but
the absence of these words does not mean that a statement is not
forward-looking. These forward-looking statements include
statements regarding Cytek’s mission, product plans and business
strategies. These statements are based on management’s current
expectations, forecasts, beliefs, assumptions and information
currently available to management. These statements also deal with
future events and involve known and unknown risks, uncertainties
and other factors that may cause actual results, performance or
achievements to be materially different from the information
expressed or implied by these forward-looking statements. Factors
that could cause actual results to differ materially include risks
and uncertainties such as those relating to global economic and
market conditions; Cytek’s dependence on certain sole and single
source suppliers; competition; market acceptance of Cytek’s current
and potential products; Cytek’s ability to manage the growth and
complexity of its organization, maintain relationships with
customers and suppliers and retain key employees; Cytek’s ability
to maintain, protect and enhance its intellectual property; and
Cytek’s ability to continue to stay in compliance with its material
contractual obligations, applicable laws and regulations. You
should refer to the section entitled “Risk Factors” set forth in
Cytek’s Quarterly Report on Form 10-Q filed with the SEC on August
8, 2023 and other filings Cytek Biosciences makes with the SEC from
time to time for a discussion of important factors that may cause
actual results to differ materially from those expressed or implied
by Cytek’s forward-looking statements. Although Cytek believes that
the expectations reflected in the forward-looking statements are
reasonable, it cannot provide any assurance that these expectations
will prove to be correct nor can it guarantee that the future
results, levels of activity, performance and events and
circumstances reflected in the forward-looking statements will be
achieved or occur. The forward-looking statements in this press
release are based on information available to Cytek as of the date
hereof, and Cytek disclaims any obligation to update any
forward-looking statements provided to reflect any change in its
expectations or any change in events, conditions, or circumstances
on which any such statement is based, except as required by law.
These forward-looking statements should not be relied upon as
representing Cytek’s views as of any date subsequent to the date of
this press release.
Media Contact:Stephanie
OlsenLages & Associates(949) 453-8080stephanie@lages.com
Investor Contact:Paul
GoodsonHead of Investor RelationsCytek
Biosciencespgoodson@cytekbio.com
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Cytek Biosciences (NASDAQ:CTKB)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024